Pulmonary arterial hypertension (PAH) is a cardiovascular disorder associated with enhanced proliferation and suppressed apoptosis of pulmonary arterial smooth muscle cells (PASMCs). Heterozygous mutations in the type II receptor for bone morphogenetic protein (BMPR2) underlie the majority of the inherited and familial forms of PAH. The transforming growth factor b (TGFb) pathway is activated in both human and experimental models of PAH. However, how these factors exert pro-proliferative and anti-apoptotic responses in PAH remains unclear. Using mouse primary PASMCs derived from knock-in mice, we demonstrated that BMPR-II dysfunction promotes the activation of small mothers against decapentaplegiaindependent mitogen-activated protein kinase (MAPK) pathways via TGFb-associated kinase 1 (TAK1), resulting in a pro-proliferative and anti-apoptotic response. Inhibition of the TAK1-MAPK axis rescues abnormal proliferation and apoptosis in these cells. In both hypoxia and monocrotaline-induced PAH rat models, which display reduced levels of bmpr2 transcripts, this study further indicates that the TGFb-MAPK axis is activated in lungs following elevation of both expression and phosphorylation of the TAK1 protein. In ex vivo cell-based assays, TAK1 inhibits BMP-responsive reporter activity and interacts with BMPR-II receptor. In the presence of pathogenic BMPR2 mutations observed in PAH patients, this interaction is greatly reduced. Taken together, these data suggest dysfunctional BMPR-II responsiveness intensifies TGFb-TAK1-MAPK signalling and thus alters the ratio of apoptosis to proliferation. This axis may be a potential therapeutic target in PAH.
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a severe vascular disorder characterized by narrowing and obliteration of the small pulmonary arteries due to abnormal proliferation of endothelial and smooth muscle cells. Pulmonary vasoconstriction and vascular remodelling leads to elevation of pulmonary artery pressure and, in the absence of an effective therapy, eventual right-heart failure and death. Heterozygous non-sense mutations in the gene encoding the type II receptor for bone morphogenetic protein (BMPR-II), a member of the TGFb receptor family, underlie the majority of inherited and familial forms of PAH (1) . Levels of BMPR2 transcripts and proteins are reduced in the lungs in both familial and sporadic PAH patients with and without BMPR2 mutation (2, 3) .
BMPR-II-mediated signalling regulates vascular cell survival and proliferation, but the underlying mechanisms are complicated. BMP2 and 7 inhibit the proliferation of human and rat smooth muscle cells (4, 5) against decapentaplegia (SMAD) pathway (6) . In pulmonary arterial smooth muscle cells (PASMCs) isolated from PAH subjects (PAH-PASMCs), the anti-proliferative effect of BMPs (2, 4, 7) is greatly reduced (7) . Furthermore, BMP-promoted apoptosis in PAH-PASMCs with reduced BMPR-II protein levels is attenuated (8) . Similarly, TGFb signalling accelerates proliferation in PAH-PASMCs, whereas it inhibits proliferation in normal PASMCs (7) . Elevated TGFb activity has been reported in rat monocrotaline and hypoxia models of PAH, and inhibitors of the TGFb type I receptor (ALK5) prevent the development and progression of disease in these models (9, 10) . These findings suggest the involvement of an activated TGFb pathway in PAH.
TGFb superfamily ligands signal through both SMADdependent and SMAD-independent pathways. SMAD signalling occurs via either SMAD2/3 (TGFb) or SMAD1/5/8 (BMP), which translocate to the nucleus with the common SMAD (SMAD4) to directly regulate target gene transcription (11) . BMPs and TGFbs have both been reported to activate SMAD-independent mitogen-activated protein kinase (MAPK) signalling pathways, including ERK, JNK and p38MAPK (6) . Phosphorylation of p38MAPK and ERK1/2 is increased in PAH-PASMCs and experimental models of PAH (12 -16) . Inhibition of MAPK decreases the excessive proliferation of PAH-PASMCs (3) and prevents progression of the disease in model systems, suggesting that SMAD-independent pathways play a key role in disease pathogenesis. However, the molecular mechanism by which TGFb-induced SMADindependent pathways might be activated consequent to impaired BMPR-II signalling remain unknown.
TGFb-associated kinase 1 (TAK1), a member of the MAPK kinase kinase (MAPKKK) family, has been shown to be an important regulator of SMAD-independent MAPK kinase activation in both the TGFb and BMP signalling pathways. TAK1 modulates a number of processes ranging from innate immune responses to patterning and differentiation via several signalling molecules, including p38MAPK, ERK, JNK, NFkappaB and TCFbeta-catenin. TAK1 also facilitates cross talk between signalling pathways. Such links via TAK1 have been established between TGFb and oncogenic R-Ras in the promotion of tumourigenesis (17) and between BMP and PI3K/Akt in cardiac cell growth and survival in the postnatal heart (18) . We hypothesized that the activation of SMAD-independent MAPK pathways in PAH consequent to impaired BMPR-II signalling is mediated via TAK1.
In this report, we demonstrated that in mouse PASMCs, BMPR-II dysfunction promotes the activation of SMADindependent MAPK pathways via TAK1 resulting in a pro-proliferative and anti-apoptotic response. Inhibition of the TAK1-MAPK axis rescues abnormal proliferation and apoptosis in these cells. We provide in vivo support of the in vitro findings in two independent PAH rat models, in which the TGFb-MAPK axis is activated following elevation of both the expression and phosphorylation of the TAK1 protein. In ex vivo cell-based assays, TAK1 interacts with BMPR-II receptor and in the presence of pathogenic BMPR2 mutation this interaction is greatly reduced. TAK1 attenuates BMP signalling by inhibiting the phosphorylation of the SMAD1 protein.
RESULTS

BMPR-II haploinsufficiency potentiates TGFb signalling, exerting a pro-proliferative response in mouse primary PASMCs
The effect of reduced levels of BMPR-II on TGFb signalling was investigated in mouse primary PASMCs and hypoxiainduced PAH rat lungs. The level of plasminogen activator inhibitor (PAI-1) transcripts was determined as a measure of TGFb signalling (9, 10) . PAI-1 expression was increased in knock-in mouse primary PASMCs with a PAH-associated bmpr2 nonsense mutation (bmpr2 R899X +/2 ) compared with wild-type PASMCs (bmpr2 +/+ ) (Fig. 1A) . Reduced levels of transcripts for bmpr2 and the inhibitor of DNA binding (Id1), a known BMP target, were seen in mutant cells (see Supplementary Material, Fig. S1A and B) . Increased PAI-1 expression was also observed in hypoxic rat lung tissues compared with normoxic control tissues (Fig. 1B) with a significant decrease in bmpr2 transcripts (Supplementary Material, Fig. S1C ). Taken together, these data suggest a link between dysfunctional BMPR-II-mediated signalling and activation of the TGFb pathway.
Proliferation was increased in mutant PASMCs compared with wild-type cells (Fig. 1C) . As in human control and PAHPASMCs (7), TGFb1 stimulation inhibited proliferation in wild-type mouse PASMCs but promoted proliferation in mutant cells (Fig. 1D) . Inhibition of p38MAPK signalling by SB203580 reduced the TGFb1-stimulated cell proliferation in mutant cells. In these cells, the basal level of p38MAPK phosphorylation is higher, and TGFb1 further activates p38MAPK phosphorylation ( Fig. 1E and F) . Taken together, these data suggest that the pro-proliferative response of mutant cells to TGFb1 is mediated via the SMAD-independent p38MAPK pathway.
Small molecule inhibitors of the TGFb -MAPK axis rescue abnormal cell proliferation and apoptosis in mouse PASMCs
We examined the role of the TGFb-mediated SMADindependent MAPK axis on pro-proliferative activity of bmpr2 R899X +/2 PASMCs by chemical agents that selectively inhibit TGFb and p38MAPK pathways. For inhibition of the TGFb pathway, we employed SD208 which is a known inhibitor of ALK5, a TGFb type I receptor, while SB203580 was used to inhibit the p38MAPK pathway. ALK5 and p38MAPK inhibitors inhibited proliferation in mutant cells in both the absence ( Fig. 2A) and presence of TGFb1 stimulation (Fig. 2B) , while inhibition of p38MAPK had no discernible effect on wild-type cells. We further investigated whether TAK1, a known activator of the p38MPK pathway, is involved in exerting the pro-proliferative activity in mutant cells. Treatment with the TAK1 inhibitor (5Z)-7-Oxozeaenol inhibited proliferation in a dose-dependent manner in mutant but not wild-type cells (Fig. 2C) . Oxozeaenol also reduced TGFbstimulated mutant cell proliferation in a dose-dependent manner (Fig. 2D) .
Next, cysteinyl aspartate protease (caspase) activity was used to measure the effect of p38MAPK, ALK5 and TAK1 inhibitors on apoptosis in mutant cells. The basal activity Human Molecular Genetics, 2012, Vol. 21, No. 11 2549 level of caspases 3 and 7 was attenuated in mutant cells compared with the wild-type (Fig. 3A) , and mutant cells showed a greater response to staurosporine, a known inducer of caspasedependent pathways, than wild-type cells (Fig. 3B) . Treatment with the ALK5 inhibitor SD208 was able to promote apoptosis in both wild-type and mutant cells in the absence (Fig. 3C ) and the presence of TGFb1 stimulation (Fig. 3D) , and inhibition of p38MAPK with SB203580 modestly enhanced apoptosis in both wild-type and mutant cells. Oxozeaenol promoted apoptosis in a dose-dependent manner and its pro-apoptotic effects were higher in mutant PASMCs than in the wild-type at the two highest doses used (Fig. 3E ). Consistent with our proliferation data, oxozeaenol induced apoptosis in mutant cells in the presence of TGFb stimulation in a dose-dependent manner (Fig. 3F ).
In addition to activating p38MAPK, the TAK1 pathway has been shown to activate ERK phosphorylation, which is increased in PAH-PASMCs (3) and experimental PAH animal models (12) (13) (14) (15) (16) . Similar to the response to oxozeaenol and SB203580 treatment, the ERK inhibitor, U0126, activated caspase 3/7 activity in the absence (Supplementary Material, Western blot analysis of total TAK1 in rat lung tissues identified a long and a short isoform and hence designated here as TAK1-LF and TAK1-SF, respectively (Supplementary Material, Fig. S4A ). Phosphorylation of neither the long nor the short form was observed in control rat lung tissues (Fig. 4B) . Interestingly, only the TAK1-SF was phosphorylated (Thr184/ 187) in hypoxic rat lungs after 1 ( Fig. 4B and C) and 2 weeks (Supplementary Material, Fig. S4B and C), but not after 2 days. TAK1-SF was also activated following monocrotaline treatment at 1 week but not at 2 or 4 weeks ( Fig. 4D and E and Supplementary Material, Fig. S4D ). The specificity of TAK1-SF was investigated in HEK293 cells. In these cells, phosphorylated TAK1-SF but not the TAK1-LF was detected which is consistent with the manufacturer's data (Cell Signaling). The specificity of this protein was tested using oxozeaenol, SMAD1 overexpression and BMP9 stimulation, all of which inhibited phosphorylation, indicating that this protein is TAK1-specific (Supplementary Material, Fig. S4E ). The activation of downstream MAPK pathways was investigated in monocrotaline-treated rat lungs. Because treatment with the ERK inhibitor, U0126, induced more pro-apoptotic activity than the p38MAPK inhibitor, SB203580 (compare Supplementary Material, Fig. S2A and B with Supplementary Material, Fig. S3C and F, respectively), phosphorylation of ERK1/2 was examined as representative of MAPK phosphorylation. Following 3 weeks of monocrotaline treatment, phosphorylation of ERK1/2 in the lungs was elevated (Fig. 4F and  G) , while no significant increase was observed after 2 weeks of hypoxic induction (Supplementary Material, Fig. S4F ).
Signalling crosstalk between SMAD1 and TAK1-mediated pathways
We next investigated the effect of canonical BMP-SMAD signalling on TAK1 activity. Following BMP9 stimulation, a reduced level of endogenous TAK1-SF phosphorylation was observed (Supplementary Material, Fig. S5A ) in HEK293 cells. In these cells, BMP9 stimulation also inhibited transiently overexpressed TAK1. Reduced level of TAK1 phosphorylation was seen following SMAD1 overexpression ( Supplementary  Material, Fig. S5B ). In the presence of an increasing amount of overexpressed TAK1, the SMAD1-mediated inhibition of TAK1 is attenuated (Supplementary Material, Fig. S5C ).
The effect of TAK1 on BMP signalling was then investigated using a BMP-responsive 3GC-lux reporter (19) . Overexpression of TAK1 inhibited reporter activity in HEK293 cells (Fig. 5A) , and transfection of equimolar concentrations of either BMPR-II or type I receptors failed to rescue this TAK1-mediated inhibition (Supplementary Material, Fig. S6A ). Moreover, overexpression of SMAD1 alone enhanced reporter activity, but SMAD1-mediated reporter activation was markedly reduced in the presence of TAK1 (Supplementary Material, Fig. S6B ). Transfection of increasing amounts of TAK1 demonstrated that the inhibition of 3GC2-lux reporter activity was dose-dependent (Fig. 5B) . TAK1-mediated inhibition of BMP signalling was independently confirmed by overexpression of an excess amount of BMPR-II receptor or SMAD1 relative to TAK1 which rescued reporter activity (Supplementary Material, Fig. S6C and Fig. 5C ) and through the use of a selective inhibitor of TAK1 (Oxozeaenol) which promoted BMPR-II-mediated reporter activation in a dose-dependent manner (Fig. 5D ).
TAK1 interacts with the BMPR-II receptor
Finally, the link between dysfunctional BMPR-II responsiveness and activation of TGFb-TAK1-MAPK signalling was investigated. TAK1 interacts with the type II receptor for TGFb1 namely TGFBRII (20) . To investigate the efficiency of a potential interaction between TAK1 and the BMPR-II receptor, fluorescence and enzyme-based mammalian twohybrid assays were performed (Fig. 6A) . Co-expression of TAK1 and BMPR-II generated readily detectable dual fluorescence (Fig. 6Biii) , suggesting an interaction between BMPR-II and TAK1. Overexpression of BMPR-II with ALK3, a known The relative caspase activity of untreated cells was set at 100. Data are presented as the mean + SD from three independent experiments. The relative caspase activity of both wild-type and mutant cells was set at 100. * P , 0.05 and * * * P , 0.001 compared with wild-type, mutant or cells stimulated with TGFb1.
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BMPR-II interactor (21), generated greater dual-fluorescence than cells transfected with BMPR-II and TAK1, indicating a weaker interaction between BMPR-II and TAK1 than that observed between BMPR-II and ALK3 (Fig. 6Biv) . Consistent with the results obtained by fluorescence microscopy, the determination of fluorescence intensity revealed that the efficiency of the interaction between TAK1 and BMPR-II is weaker than that between BMPR-II and ALK3 (Supplementary Material, Fig. S7A and B) . To verify these findings, an enzyme-based (luciferase and b-galactosidase) assay was used to evaluate the interactions between BMPR-II and TAK1 or ALK3 (Fig. 6C) . Overexpression of BMPR-II with TAK1 generated 200-fold higher luciferase activity compared with reporter alone, further confirming an interaction between these two proteins (Fig. 6D) . In addition, we were able to replicate the finding that the interaction between BMPR-II and TAK1 is weaker than that of BMPR-II and ALK3 (Fig. 6E) . Of interest, we noted that the interaction between BMPR-II and TAK1 was significantly reduced by introducing known pathogenic missense BMPR2 mutations commonly identified in PAH subjects (Fig. 6F) .
DISCUSSION
The present study provides insight into the mechanism by which dysfunctional BMPR-II and overactive TGFb-mediated signalling contributes to both pro-proliferative and antiapoptotic responses leading to the vascular remodelling observed in PAH. In this study, we present evidence that suggest that BMPR-II deficiency activates TGFb signalling through the SMAD-independent TAK1-MAPK pathway exerting abnormal proliferation and apoptosis in bmpr2
PASMCs. Inhibition of this TAK1-MAPK axis rescues both abnormal proliferation and apoptosis. Furthermore, we provide in vivo support of our in vitro findings that the TAK1-mediated MAPK pathway is activated in both monocrotaline and hypoxia-induced PAH rat models. We demonstrate that TAK1, a kinase which activates MAPK pathways, binds to the BMPR-II receptor. In the presence of PAH-causing BMPR2 mutations, this interaction between BMPR-II and TAK1 is greatly reduced, which may make TAK1 accessible to TGFb signalling. This study demonstrated several lines of evidence to suggest that the pro-proliferative response of TGFb signalling as a consequence of impaired BMPR-II activity is mediated via the TGFb-TAK1-MAPK axis. We demonstrated that p38MAPK activity and TAK1 expression are increased in bmpr2-deficient hyperproliferative PASMCs and that the excessive proliferation can be selectively reversed by inhibition of both p38MAPK and TAK1 supporting the finding that inhibition of p38MAPK reverses the vascular dysfunction that is induced by hypoxia (12) . We present evidence that the apoptotic resistant phenotype observed in PAH resulting from reduced levels of BMPR-II is modulated via the activation of TAK1-dependent MAPK pathways. Apoptosis is attenuated in mutant PASMCs, an effect that is mitigated by the inhibition of MAPK pathways, including TAK1, p38MAPK and ERK. These results imply that BMPR2 deficiency activates TGFb-TAK1-MAPK signalling, which may alter the ratio of cell apoptosis to proliferation and thereby mediating pulmonary vascular medial hypertrophy (Fig. 7A and B) .
Both synergistic and antagonistic influences of TAK1 on SMAD-dependent pathways have been reported. TAK1 has been shown to be an essential regulator of BMP signalling and is required for the morphogenesis, growth and maintenance of cartilage (22) . In contrast, TAK1 has also been shown to interact with SMAD1 -6, which interferes with BMP-induced SMAD signalling in murine mesenchymal progenitor cells (23) . In addition, TAK1 inhibits TGFb-mediated SMAD activity by promotion of p38MAPK signalling in prostate cancer cells (24) . In this study, we found that TAK1 inhibits SMAD activity and that the inhibitory effect of TAK1 can be overcome by the promotion of SMAD-mediated signalling, which acts to inhibit TAK1 phosphorylation, indicating a signalling crosstalk between these two pathways (23). These observations support a model in which TAK1 activity is restricted and the protein is retained by the SMADs and/or cellular receptors, including BMPR-II and TGFBRII. TAK1 was found to be a BMPR-II-associated protein (18) and, in the presence of pathogenic missense BMPR2 mutations (21) , the efficiency of the interaction between TAK1 and * P , 0.05, * * P , 0.01 and * * * P , 0.001 compared with the reporter.
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BMPR-II is markedly reduced. This may impact BMPR-II signalling in two distinct pathways ( Fig. 7A and B) . First, an increase in accessible TAK1 may attenuate SMAD signalling to below threshold level. Second, the increased availability of TAK1 may activate SMAD-independent pathways triggered by the overactive TGFb signalling as well as by the 'second hit', including inflammation and environmental stress (25, 26) .
In an ex vivo cell-based model, hypoxia has been shown to increase TAK1 activity (27) . Increased expression and phosphorylation of TAK1 in two independent PAH rat models (chronic hypoxia or monocrotaline injection) supports the involvement of activated TAK1-mediated pathway in PAH. Elevated levels of phosphorylated ERK1/ 2, a downstream target of TAK1, in monocrotaline-induced PH rat lungs further implies the relevance of the TAK1-MAPK axis to PAH. As TAK1 is located at the crossroad of several signalling pathways, the challenge ahead lies in unravelling the context in which it acts together with cellular consequences.
In summary, we have demonstrated that BMPR2 deficiency exerts pro-proliferative and anti-apoptotic responses through TGFb-mediated SMAD-independent pathways and that TAK1 plays an essential role in fine tuning both SMADdependent and -independent effects in PAH. TAK1-MAPK signalling is involved in cardiac remodelling following myocardial infarction (28) and plays a central role in the maladaptive response to sustained pressure overload (29) . Given the therapeutic potential of TAK1 inhibition in pancreatic cancer (30) and myocardial dysfunction caused by chronic pressure overload (29) , we propose that the inhibition of the TGFb-MAPK axis via TAK1 might provide a novel and effective therapeutic intervention in PAH. 
MATERIALS AND METHODS
Further details are provided in Supplementary Materials and Methods.
RNA isolation, cDNA synthesis and reverse-transcriptase PCR (RT -PCR)
Complementary DNA (cDNA) was synthesized using random primers (Roche) and MMLV Reverse Transcriptase (Promega) using RNAs isolated from lung samples as described (31) . PCR was carried out using Hi-Fidelity Extensor Master Mix (ABgene).
Cell culture, transient transfection, enzymatic assay and western blots
Cell culture and transfections were carried out as described elsewhere (21, 32) . Luciferase and b-galactosidase activities were determined with the Dual-light Reporter Assay (Applied Biosystems) using an ORION-II Plate Luminometer (Berthold) according to the manufacturer's protocols. BMP-responsive reporter assay in mammalian cells was performed as previously described (21) . Western blots were carried out using anti-phospho-specific p38MAPK (Thr180/ Thr182), TAK1 (Thr184/187), ERK1/2 (Thr202/Tyr204) and total TAK1 (Cell Signaling) antibodies following the manufacturer's protocols. To confirm equal loading, the membranes were stripped and re-probed with anti-b-actin antibody (Cell Signaling).
Determination of protein -protein interactions, quantification of proliferation and apoptosis of mouse primary PASMCs
Efficiency of protein -protein interactions between TAK1 and BMPR-II in mammalian cells was determined as previously reported (33) . Relative rate of proliferation and apoptosis of mouse PASMC was carried out using CellTiter 96 w Aq ueous One Solution Cell Proliferation Assay and Caspase-Glo w 3/7 Assay (Promega) following the manufacturer's instruction.
The hypoxia and monocrotaline-induced PAH rat models
Two experimental PAH models induced by chronic hypoxia and monocrotaline (MCT) were employed. Chronic hypoxia rats were exposed to 10% O 2 in the normorbaric chamber and MCT rats were injected subcutaneously in a hind limb with MCT (60 mg/kg, Sigma). The lungs were collected from control, 2 days, 1 week, 2 weeks hypoxia rats (n ¼ 3-4) and 1 week, 2 weeks, 3 weeks and 4 weeks after MCT (n ¼ 3 -4) injection and stored at 2808C.
Statistics
The data were expressed as mean + SD and analysed using the Student's t-test. One-way analysis of variance followed by Turkey's post hoc tests were carried out for the comparison of multiple means. A P-value of ≤0.05 indicated statistical significance. 
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